The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease
Study Rationale:
Subcellular structures called mitochondria perform many critical activities for brain cells. They generate enormous amounts of energy and remove the calcium that floods into neurons... -
Biomarkers, 2021The Development of Novel Probes for Imaging Glucocerebrosidase Activity in Parkinson’s Disease
Study Rationale:
Mutations that disable glucocerebrosidase (GBA), a protein that strips sugars from molecules in the membranes of brain cells, are associated with Parkinson’s disease (PD)... -
Research Grant Supplement, 2021Profiling the Removal of Damaged Mitochondria in Stem Cell-Derived Brain Cells from People with Parkinson’s
Promising Outcomes of Original Grant:
Our previous work has shown that metabolic failure plays a critical role in the pathology of Parkinson’s disease (PD). A plethora of evidence from different... -
Priority Biology, 2021Gene Expression Changes Induced by Alpha-Synuclein
Study Rationale:
Deposits of the alpha-synuclein protein are the key cellular pathology recognized to drive the progression of Parkinson’s disease leading to the death of neurons. The alpha-synuclein... -
Biomarkers, 2021Use of Neuronal Exosomes to Predict Parkinson’s Disease
Study Rationale:
In Parkinson’s disease (PD), the build-up of alpha-synuclein inside nerve cells leads to formation of abnormal clumps and death of dopamine-producing cells and other neurons. By the... -
Therapeutic Pipeline Program, 2021Development of Compounds that Destroy Alpha-Synuclein Aggregates for the Treatment of Parkinson’s Disease
Study Rationale:
Multiple lines of evidence indicate that alpha-synuclein forms aggregates similar to those adopted by infectious prion proteins, and that these toxic clusters are responsible for the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.